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pas de poussée de psorisis (12%)—no answers (4%)—
Psoriasis had a greater adverse affect on patients with
crise: PDI score = 20.24 (sd 17.52) than the patient
without actual crise PDI score = 8.98 (sd 11.34). This dif-
ference was signiﬁcative p < 0.00001. CONCLUSION:
These results highlight the value of appropriate and rele-
vant psychological and medical environment for patients
suffering from psoriasis.
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DEVELOPMENT AND VALIDATION OF A
HEALTH-RELATED QUALITY OF LIFE
INSTRUMENT FOR WOMEN WITH 
MELASMA
Balkrishnan R1, McMichael AJ1, Feldman SR1, Camacho F1,
Chren MM2
1Wake Forest University School of Medicine, Winston-Salem,
NC, USA; 2University of California San Francisco, San
Francisco, CA, USA
OBJECTIVES: Melasma, a facial pigmentary condition
affecting women, can have signiﬁcant emotional and psy-
chological effects on those affected. Our purpose was 
to develop and validate a disease-speciﬁc HRQoL instru-
ment to identify the areas of the patient’s life most
impaired by melasma as well as the effects of the condi-
tion on their level of functioning in correlation with
disease severity, the Melasma Quality of Life scale
(MELASQOL). METHODS: A random sample of 102
women identiﬁed by an investigator as having melasma
were evaluated by the investigator using the Melasma
Area and Severity Index (MASI). The patients were then
anonymously surveyed with the SKINDEX-16, the Fear
of Negative Evaluation scale, the Dermatology Life
Quality Index (DLQI), a specially-developed skin dis-
coloration evaluation questionnaire, and a measure of
perceived life quality difference without melasma. The
10-item MELASQOL scale was devised from the 
comprehensive HRQoL assessment battery. RESULTS:
The psychometric properties of the MELASQOL were
comparable with the properties of the DLQI and the
SKINDEX-16. The MELASQOL scores were highly cor-
related with the other HRQoL measures. The discrimi-
natory ability of the MELASQOL is superior to the
SKINDEX-16 and the DLQI for melasma. The three life
domains most adversely affected by melasma (social life,
recreation/leisure, and emotional well-being) were high-
lighted by this instrument. These were the same three
areas of life that patients believed would improve the
most if they no longer were affected by the disease. CON-
CLUSION: The MELASQOL can be used to objectively
evaluate the effect of melasma on a patient’s HRQoL. The
high correlation with the DLQI, the SKINDEX-16, and
the skin discoloration questionnaire suggests that the new
scale is a valid instrument, which can be used to monitor
the level of impairment individuals suffer due to their
melasma.
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OBJECTIVE: To examine the effect of mail-based inter-
ventions on appropriate prescribing of COX-2 inhibitors
for patients at increased risk for adverse gastrointestinal
(GI) events. METHODS: The 600 highest-volume pre-
scribers of COX-2 inhibitors were identiﬁed from a health
plan database from October to December 2001, and 
randomly assigned to one of three intervention groups: 1)
High intervention (proﬁle incorporating probability of GI
bleed); 2) Medium intervention (pharmacy claim infor-
mation only; no probability modeling); and 3) No inter-
vention. Intervention physicians received monthly proﬁles
for 6 months (May 2002 through October 2002). Risk
factors used to calculate the probability of GI bleed
included: history of ulcer, arthritis, GI bleed, concurrent
use of anticoagulants or oral steroids, and age greater
than 65 years. Appropriate usage metrics were changes in
mean proportion of patients with each risk factor and
percentage of COX-2 inhibitor prescriptions out of all
anti-inﬂammatory medications. Proportions were com-
pared between intervention groups. Statistical analyses
were performed using multivariate Generalized Estimat-
ing Equations (GEE). RESULTS: Baseline proportions 
of COX-2 prescriptions for high intervention, medium
intervention, and no intervention groups were 0.602 ±
0.192, 0.603 ± 0.202, and 0.589 ± 0.202, respectively; 5-
month post-intervention proportions were 0.587 ± 0.269,
0.588 ± 0.253, and 0.619 ± 0.255, respectively; adjusted
GEE coefﬁcients were -0.048 (p = 0.001), -0.044 (p =
0.002), for the high and medium intervention groups,
respectively. Proportion of patients with a history of ulcer,
GI bleed, and arthritis also increased by 33%, 41%, and
26%, respectively, across all groups. However, differences
between groups were not signiﬁcant. CONCLUSIONS:
Preliminary analysis has shown a positive change in pre-
scribing patterns. First, there was a decrease in the pro-
portion of patients receiving COX-2 inhibitors. Second,
in patients receiving COX-2 inhibitors, the proportion of
patients with select risk factors (history of ulcer, GI bleed,
and arthritis) increased.
